Critical medicines shortages persist in the European Union, indicating a dire need for regulatory reform, as highlighted in a recent report by the European Court of Auditors unveiled on Wednesday, September 17th.
From January 2022 to October 2024, the EU documented shortages of 136 crucial medicines, shedding light on the severity of the issue.
Although medicine shortages have been an ongoing challenge, the past two years have witnessed a notable surge within the bloc, as emphasized by Klaus Heiner Lehne, the lead auditor of the report.
The root causes of these shortages are diverse and complex, with one significant factor being the vulnerabilities present in the supply chains. A substantial portion of medicines utilized in the EU originates from Asia.
According to Lehne, “The pharmacy of the world is in China or India,” underscoring that active pharmaceutical ingredients, the backbone of most medicines, are frequently produced by a limited number of companies, often situated in Asia. This heavy reliance on Asian production is exemplified by popular medications like paracetamol and ibuprofen, where the EU’s supply is entirely dependent on Asian sources.
Healthcare responsibilities primarily lie within the purview of member states, with the European Medicines Agency (EMA) stepping in to offer support solely during health crises.
Consequently, proactive measures to address critical medicine shortages are predominantly handled at the national level. Recent scarcity incidents prompted certain countries to revise their regulations regarding medicine stockpiling, potentially exacerbating shortages in other EU nations, as indicated in the auditors’ findings.
One alarming case highlighted in the report pertains to the critical shortage of thrombolytics, essential for treating individuals at high risk of heart attacks or strokes, whether in prevention or post-incident scenarios.
Upon EMA’s intervention, it was discovered that the production of thrombolytics was centralized at a singular manufacturing site. To alleviate the supply shortage, the establishment of an additional manufacturing site was necessary, albeit time-consuming.
To address these challenges, the auditors recommended enhancing the reporting mechanisms to EMA for improved coordination in meeting member states’ medicine demands and advocating for diversification in medicine supply chains.
Lehne’s forecast for the upcoming winter predicts further shortages, highlighting the availability of strategies to mitigate such occurrences, provided they are effectively utilized.
Currently, the EU Commission has proposed legislative measures, including the Critical Medicines Act and new pharmaceutical legislation, awaiting approval from the European Parliament and the Council.
As the EU navigates these critical healthcare challenges, the need for comprehensive reforms and proactive strategies is paramount to safeguarding public health across the bloc.
The Impact of Legislative Proposals on Medicines Shortages
The legislative proposals initiated by the EU Commission, notably the Critical Medicines Act and associated pharmaceutical legislation, hold the potential to address the root causes of medicines shortages within the EU.
It is imperative to scrutinize and expedite the approval of these legislative measures to fortify the healthcare infrastructure and mitigate the recurrent issue of critical medicines shortages.
Enhancing Medicines Supply Chains for Resilience
Diversifying the sources of medicine production and supply beyond Asia could bolster the resilience of the EU’s healthcare system, reducing its vulnerability to external disruptions and shortages.
Collaborative Efforts for Sustainable Healthcare Solutions
Collaboration between member states, regulatory bodies like EMA, pharmaceutical companies, and auditors is essential to implement sustainable solutions that ensure continuous access to critical medicines across the EU.
Strengthening Healthcare Preparedness and Response
Investing in proactive measures, such as improved reporting systems, early intervention strategies, and robust contingency plans, can enhance the EU’s preparedness and response to medicines shortages, safeguarding public health during crises.
Tags: regulatory
Read more on euobserver.com